Gut–brain axis

Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair

Retrieved on: 
Wednesday, May 17, 2023
Precigen, BIO, Gilead Sciences, National Science Advisory Board for Biosecurity, Central nervous system, Therapy, University, Massachusetts Institute of Technology, Health, Biotechnology, National Science Foundation, DSM-IV codes, Social entrepreneurship, Research, MIT, Genomics, Doctor of Philosophy, CNS, Exact sciences, Advisory board, Gut–brain axis, McKinsey & Company, Entrepreneurship, Santa Clara University, Patient, Biotechnology Innovation Organization, Chemical engineering, SAN, Bloom, Merck, Synthetic biology, Affymetrix, Pharmaceutical industry, Trustee

Dr. Colón has over 25 years of experience in biopharma, genomics, diagnostics, healthcare, industrial microbiology/biotechnology, synthetic biology, venture capital, management consulting, and entrepreneurship.

Key Points: 
  • Dr. Colón has over 25 years of experience in biopharma, genomics, diagnostics, healthcare, industrial microbiology/biotechnology, synthetic biology, venture capital, management consulting, and entrepreneurship.
  • She serves on the boards of CareDx, Voyager Therapeutics, the MIT Corporation (MIT's Board of Trustees) and the Biotechnology Innovation Organization (BIO), and is also Executive Chair (formerly CEO) of ProterixBio.
  • "We are thrilled to welcome Dr. Colón as the Chair of our Board of Directors," said Christopher Reyes, PhD, founder and CEO of Bloom Science.
  • "Bloom Science is the leading microbiome company dedicated to developing innovative therapies for neurological diseases through the gut-brain connection," said Dr. Colón.

Danone North America Selects Fellowship Grant Recipients to Propel Gut Microbiome, Yogurt and Probiotic Research Forward

Retrieved on: 
Tuesday, May 9, 2023
Gallic acid, Food, University, Bureau of Oceans and International Environmental and Scientific Affairs, NGP, Probiotic, Harvard University, PBC, University of Texas at Austin, Research, Brain, Doctor of Philosophy, Gut–brain axis, Danone, White House conference, Investment, Yogurt, Immune system, Danone North America, Biology, Knowledge, Faculty, Ecosystem, Food security, Conference, Dietary supplement, Health, Hunger

WHITE PLAINS, N.Y., May 9, 2023 /PRNewswire/ -- Danone North America, the purpose-driven food and beverage leader, is proud to announce it has selected this year's recipients of the 2022-2023 Annual Gut Microbiome, Yogurt and Probiotic Fellowship Program. This year, Madison Adamthwaite of Harvard University and Nam Than of The University of Texas at Austin have been awarded $25,000 each to conduct research which will help to further the understanding of the Gut Microbiome, Yogurt and Probiotics. The 2022-2023 program marks eleven years and over half a million dollars' worth of grants awarded to empower creative minds and nurture scientific advances.

Key Points: 
  • The impact of yogurt, probiotics and the gut microbiome may be linked to full-body health impacts including brain, digestive and immune function.
  • "It is Danone North America's mission to bring health through food to as many people as possible and this fellowship grant helps us do just that," said Miguel Freitas, PhD, Vice President of Health and Scientific Affairs at Danone North America.
  • The Danone Fellowship Grant was established in 2010 to provide funding for novel studies of yogurt, probiotics, and the gut microbiome.
  • The 2023 Fellowship Grants for Gut Microbiome, Yogurt and Probiotic studies are a part of this commitment.

Amare Global Appoints Kent Wood as Chief Operating Officer

Retrieved on: 
Tuesday, May 2, 2023
Marketing, Parent, GBX, Grandparent, Movement, Acquisition, Gut–brain axis, Health, CFO, Growth, Management, LEHI

LEHI, Utah, May 2, 2023 /PRNewswire-PRWeb/ -- Amare Global, The Mental Wellness Company® and leader in all-natural mental wellness solutions, is pleased to announce the promotion of Kent Wood to Chief Operating Officer (COO). In his new role, Kent will be responsible for overseeing all global operations of the company, including finance, supply chain, IT, and legal. Kent will focus on ensuring the operational health of the business, with an emphasis on optimizing the supply chain to support the company's record-breaking growth and global expansion. In addition to his new role, Kent will continue fulfilling the responsibilities of Chief Financial Officer (CFO.)

Key Points: 
  • LEHI, Utah, May 2, 2023 /PRNewswire-PRWeb/ -- Amare Global, The Mental Wellness Company® and leader in all-natural mental wellness solutions, is pleased to announce the promotion of Kent Wood to Chief Operating Officer (COO).
  • In his new role, Kent will be responsible for overseeing all global operations of the company, including finance, supply chain, IT, and legal.
  • In addition to his new role, Kent will continue fulfilling the responsibilities of Chief Financial Officer (CFO.)
  • Joining Amare as Chief Financial Officer in 2019, Kent has played an instrumental role in the company's growth, including the successful strategic acquisition of Kyäni Inc. in 2022.

ADM and Brightseed Launch Global Partnership To Decode How The Gut Microbiome & Bioactives Impact Human Health

Retrieved on: 
Thursday, April 6, 2023
Retail, Other Health, Technology, Artificial Intelligence, Fitness & Nutrition, Agriculture, Natural Resources, Specialty, Vitamins, Supplements, Biotechnology, Science, Software, Other Science, Food, Beverage, Research, Health, ADM, Partnership, Diet, Drink, A.I, Synbiotics, Multimedia, Global health, Nutritional science, Plant, Gut–brain axis, Dietary supplement, Biology, Bacteria, Probiotic

ADM , a global leader in nutrition that powers many of the world’s top food, beverage, and health and wellness brands, and Brightseed , the bioactives company and a World Economic Forum Global Innovator, today announced a global joint partnership to develop evidence-based functional synbiotic products that target microbiome optimization with an undisclosed investment.

Key Points: 
  • ADM , a global leader in nutrition that powers many of the world’s top food, beverage, and health and wellness brands, and Brightseed , the bioactives company and a World Economic Forum Global Innovator, today announced a global joint partnership to develop evidence-based functional synbiotic products that target microbiome optimization with an undisclosed investment.
  • platform, Forager®, to decipher the molecular interactions between dietary plants and gut microbes, and their potential impact on human health.
  • View the full release here: https://www.businesswire.com/news/home/20230406005144/en/
    ADM and Brightseed Launch Global Partnership to Decode How The Gut Microbiome and Bioactives Impact Human Health (Photo: Business Wire)
    “We know from our recent research into global consumer trends that macro forces, including the lingering pandemic, have coincided with an increased demand for natural and plant-based solutions that target immune function, metabolic health, and mental well-being,” said Mark Lotsch, ADM’s president of global health and wellness.
  • ADM and Brightseed aim to launch highly efficacious synbiotics in specific health areas as functional ingredients for foods and beverages, dietary supplements, and medical foods by 2025.

Invea Therapeutics Announces Poster Presentations at Keystone Symposia Gut-Brain Axis and Digestive Disease Week (DDW2022)

Retrieved on: 
Thursday, March 17, 2022
Therapy, Time, GBA, GLOBE, Artificial intelligence, Machine learning, AI, Eosinophilic esophagitis, GI, Institute of Liver and Biliary Sciences, Primary sclerosing cholangitis, Central nervous system, Disorder, Enteric nervous system, DDW, Communication, Research, Gut–brain axis, Immune system, ML, Ulcerative colitis, Medical device

Invea Therapeutics is currently advancing programs for inflammatory Gastrointestinal (GI) and hepatobiliary disorders, including ulcerative colitis, eosinophilic esophagitis, eosinophilic gastroenteritis/duodenitis, and primary sclerosing cholangitis.

Key Points: 
  • Invea Therapeutics is currently advancing programs for inflammatory Gastrointestinal (GI) and hepatobiliary disorders, including ulcerative colitis, eosinophilic esophagitis, eosinophilic gastroenteritis/duodenitis, and primary sclerosing cholangitis.
  • The research that will be presented by Dr.
  • Dysregulation of the GBA is known to cause several functional and inflammatory GI and hepatobiliary conditions with neuropsychiatric manifestations.
  • Details of the time and location of the poster presentations are as follows:

Nichi GLOW: Japanese Beta-Glucan, in Children With Autism Spectrum Disorder, Improves Behavior, Sleep, and Gut Microbiome in a Clinical Study

Retrieved on: 
Monday, March 14, 2022
Mental Health, Research, Seniors, Children, Clinical Trials, Biotechnology, Health, Consumer, Science, BMJ, Publication, GMP, Trial of the century, Autism, Aggregation, Gut–brain axis, Food, Neurodevelopmental disorder, GN, Research, Parent, Microglia, Neurodegeneration, Sleep, Aureobasidium pullulans, Multimedia, Neuron, Amyloid, Brain, CARS, Learning, Reading, Allergen, Natural killer cell, Solution, Disease, ASD, Autism spectrum, Vaccine, Dementia

Beneficial reconstitution of gut microbiota was also reported with Nichi GLOW, which is unique from other beta glucans by its source, production method, and purity.

Key Points: 
  • Beneficial reconstitution of gut microbiota was also reported with Nichi GLOW, which is unique from other beta glucans by its source, production method, and purity.
  • One of them demonstrated his reading, writing and mathematical skills in a follow-up consulting with Dr Raghavan, developmental pediatrician & neurologist.
  • (Graphic: Business Wire)
    Autism is a neurodevelopmental disorder affecting 1 in 44 children in the developed world, with multiple causes and varying severity of manifestation.
  • Nichi GLOW controlled enterobacteria, a gut microbiome producing harmful proteins like curli and amyloid, leading to Alpha-synuclein misfolding and aggregation in the neurons, a cause of the disease ( https://doi.org/10.1101/2021.10.26.21265505 ).

Digestome Therapeutics Announces Exclusive Out-license of DGX-001 for Greater China with Zhongze Therapeutics

Retrieved on: 
Friday, February 25, 2022
Therapy, Schizophrenia, Psychiatry, Doctor of Philosophy, Vagus nerve, List of populated places in the Tibet Autonomous Region, Parkinson's disease, Lists of diseases, Government budget balance, SAN, Patient, MD, CEO, Gut–brain axis, CNS, Pharmaceutical industry, Victoria (Australia)

SAN FRANCISCO, Feb. 25, 2022 /PRNewswire/ -- Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate the central nervous system(CNS)via the gut-brain-axis, announced today the completion of an exclusive out-licensing agreement of DGX-001 in the greater China territory with Zhongze Therapeutics.

Key Points: 
  • SAN FRANCISCO, Feb. 25, 2022 /PRNewswire/ -- Digestome Therapeutics, a biotech company developing first-in-class therapeutics that stimulate the central nervous system(CNS)via the gut-brain-axis, announced today the completion of an exclusive out-licensing agreement of DGX-001 in the greater China territory with Zhongze Therapeutics.
  • "Digestome is excited to work with Zhongze Therapeutics to develop DGX-001 for the greaterChina markets," said Ken Horne, President of Digestome Therapeutics.
  • "Zhongze is thrilled to work with Digestome Therapeutics to develop DGX-001 for Chinese patients in need of innovative therapies," commented Xianbo Zhou, MD, PhD, Co-founder and CEO of Zhongze Therapeutics.
  • Our leading assets are a phase II combo drug for substance use disorders and a phase I small molecule for schizophrenia.

Vibrant submits innovative non-drug chronic idiopathic constipation treatment for FDA clearance

Retrieved on: 
Friday, December 17, 2021
Circadian rhythm, Constipation, Phase, Food, Gastrointestinal tract, OTC, FDA, Vibrant consonant, ENS, Life, Northwestern Health Sciences University, Sale, III, Harvard Medical School, CIC, Medical college, Science, University of Michigan, Review, Enteric nervous system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Safety, Patient, Gut–brain axis, Houston Methodist Hospital, Medicine, Augusta University, University, Classification, Medical College of Georgia, Defecation, Pharmaceutical industry, Medical device, Dietary supplement, Laxative

NEW YORK, Dec. 17, 2021 /PRNewswire-PRWeb/ --Vibrant has announced that the Vibrant System for chronic idiopathic constipation met its primary safety and efficacy endpoints in the V-270 pivotal trial.

Key Points: 
  • NEW YORK, Dec. 17, 2021 /PRNewswire-PRWeb/ --Vibrant has announced that the Vibrant System for chronic idiopathic constipation met its primary safety and efficacy endpoints in the V-270 pivotal trial.
  • "The goal of Vibrant is to address a real problem in chronic constipation, which has made life very challenging for those who suffer from it.
  • The new Vibrant non-drug system provides new hope to the millions of Americans who suffer from chronic idiopathic constipation without satisfactory relief from Laxatives.
  • Vibrant is a proprietary, biocompatible treatment for chronic idiopathic constipation (CIC).

Your IndividualiTEA is the Key to $500 and a Year's Supply of Tea

Retrieved on: 
Tuesday, December 14, 2021
People, Sleep, TikTok, Bacteria, Weight loss, Awareness, Friends, Association, Flora (microbiology), Yan, Polyphenol, Microbiology, Inborn errors of metabolism, Trial, Tea, Research, Mechanical philosophy, Cardiovascular disease, Derbyshire, Immune system, IG, Obesity, Council, Multimedia, Degenerative disease, Twitter, Partnership, Gut–brain axis, Health, View, Dietary supplement, Coffee, Instagram

To celebrate every sip, the Tea Council of the USA is kicking off their sixth annual #IndividualiTEA Photo Sharing Sweepstakes .

Key Points: 
  • To celebrate every sip, the Tea Council of the USA is kicking off their sixth annual #IndividualiTEA Photo Sharing Sweepstakes .
  • Tell us how tea fits into your daily routine for a chance to win $500, a year's supply of tea and an at-home tea ritual starter kit.
  • When you center yourself around a cup of polyphenol-packed true tea black, green, white, oolong or dark your mind and body benefit.
  • Tea Compounds and the Gut Microbiome: Findings from Trials and Mechanistic Studies.Nutrients,11(10), 2364. https://doi.org/10.3390/nu11102364
    View original content to download multimedia: https://www.prnewswire.com/news-releases/your-individualitea-is-the-key-...

Avalife Is Supporting the Brain Through the Stomach

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Anatomy, Digestive system, Environmental microbiology, Firmicutes, Microbiomes, Organs anatomy), Brain, Gut–brain axis, Mental health

In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.

Key Points: 
  • In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.
  • A growing body of research has revealed how closely the brain and the gut work together a phenomenon known as the "gut-brain axis."
  • About Avalife: Avalife's parent company, Avacare Global, was founded by Dr. Vikram Naik in South Africa in 1997.
  • Avacare is the company's division that is focused on holistic solutions and targets natural and complementary medicine in pursuit of that end.